Antifungal Efficacy, Safety, and Single-Dose Pharmacokinetics of LY303366, a Novel Echinocandin B, in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits
- 1 November 1998
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 42 (11) , 2898-2905
- https://doi.org/10.1128/aac.42.11.2898
Abstract
LY303366 is a novel semisynthetic derivative of echinocandin B and a potent inhibitor of fungal (1,3)-β- d -glucan synthase. The antifungal efficacy and safety of LY303366 were investigated in treatment and prophylaxis of primary pulmonary aspergillosis due to Aspergillus fumigatus in persistently neutropenic rabbits. Treatment study groups were either not treated (controls) or treated with amphotericin B (AmB) at 1 mg/kg of body weight per day or with LY303366 at 1, 5, 10, and 20 mg/kg/day. In rabbits treated with LY303366, there was a significant improvement in survival and a reduction in organism-mediated pulmonary injury measured by the number of infarcts, total lung weight, and ultrafast computerized tomography scan pulmonary lesion score. Rabbits receiving prophylactic LY303366 also demonstrated significant improvement in survival and reduction in organism-mediated pulmonary injury. AmB and LY303366 had comparable therapeutic efficacies by all parameters with the exception of reduction in tissue burden of A. fumigatus , where AmB was superior to LY303366. LY303366 demonstrated a dose-dependent effect on hyphal injury with progressive truncation, swelling, and vacuolization. LY303366 administered in single doses of 1, 5, 10, and 20 mg/kg demonstrated dose-proportional increases in the maximum concentration of drug in plasma and the area under the concentration-time curve from 0 to 72 h with no changes in plasma drug clearance. The 1-mg/kg dosage maintained plasma drug levels above the MIC for 18 h, and dosages of ≥5 mg/kg maintained plasma drug levels above the MIC for the entire 24-h dosing interval. There was no significant elevation of the concentrations of hepatic transaminases or creatinine in serum in LY303366-treated rabbits. In summary, LY303366 improved survival and decreased pulmonary injury with no apparent toxicity in the treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits.Keywords
This publication has 23 references indexed in Scilit:
- Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.Diagnostic Microbiology and Infectious Disease, 1996
- RECENT PROGRESS AND CURRENT PROBLEMS IN TREATMENT OF INVASIVE FUNGAL INFECTIONS IN NEUTROPENIC PATIENTSInfectious Disease Clinics of North America, 1996
- Semisynthetic Chemical Modification of the Antifungal Lipopeptide Echinocandin B (ECB): Structure-Activity Studies of the Lipophilic and Geometric Parameters of Polyarylated Acyl Analogs of ECBJournal of Medicinal Chemistry, 1995
- Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapyAntimicrobial Agents and Chemotherapy, 1995
- Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthaseAntimicrobial Agents and Chemotherapy, 1994
- Efficacy of Unilamellar Liposomal Amphotericin B in Treatment of Pulmonary Aspergillosis in Persistently Granulocytopenic Rabbits: The Potential Role of Bronchoalveolar D-Mannitol and Serum Galactomannan as Markers of InfectionThe Journal of Infectious Diseases, 1994
- Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosisAntimicrobial Agents and Chemotherapy, 1991
- Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasisAntimicrobial Agents and Chemotherapy, 1991
- In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Anti-Candida Activity and Toxicology of LY121019, a Novel Semisynthetic Polypeptide Antifungal AntibioticAnnals of the New York Academy of Sciences, 1988